Drugs / simpinicline
simpinicline
also known as
OC-02 · TC-6499 · OC-02 CITRATE · OC-02-cit · SIMPINICLINE CITRATE · TC-6499-12 · TC-6499-221
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02187094 | Jun 2014 → Jan 2015 | gastroparesis | Targacept Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01149200 | May → Oct 2010 | irritable bowel syndrome | Targacept Inc. | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT03633461 Comparator | Aug → Sep 2018 | dry eye syndrome | Oyster Point Pharma, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03452397 Comparator | Feb → Apr 2018 | dry eye syndrome | Oyster Point Pharma, Inc. | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | simpinicline | “nAChR agonist OC-02 (simpinicline solution) as an aqueous nasal spray” PMID 35965109 ↗ Aug 20221“OC-02 (simpinicline) nasal spray” NCT03633461 ↗ |
| Known as | OC-02 | “nAChR agonist OC-02 (simpinicline solution) as an aqueous nasal spray” PMID 35965109 ↗ Aug 2022 |
| Known as | OC-02 CITRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594254 ↗ |
| Known as | OC-02-cit | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594254 ↗ |
| Known as | SIMPINICLINE CITRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594254 ↗ |
| Known as | TC-6499 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01149200 ↗ |
| Known as | TC-6499-12 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594254 ↗ |
| Known as | TC-6499-221 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594254 ↗ |
| Action | Activate | “agonist stimulation of nAChRs in the nasal cavity” PMID 35965109 ↗ Aug 2022 |
| Modality | Small molecule | — CHEMBL4594254 ↗ |
| Route | Oral | “5mg enteric-coated oral hard gelatin capsule, administered twice daily” NCT01149200 ↗ |